CIK 0001701541 · Non-accelerated filer<br>Smaller reporting company
Black Diamond Therapeutics, Inc.
Sign in to watch- Ticker
- BDTX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 814254660
- Phone
- 617-417-5868
- Business address
- 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, 02142
- Former names
- Aset Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-19 | Behbahani Ali Director | Grant or award | +4,291 | $3.35 | $14K | 81,441 |
| 2025-06-20 | Raman Prakash Director | Grant or award | +5,526 | $2.33 | $13K | 22,519 |
| 2025-06-20 | Behbahani Ali Director | Grant or award | +6,170 | $2.33 | $14K | 77,150 |
| 2025-06-12 | Menzel Garry E Director | Grant or award · Stock Option (Right to Buy) | +30,550 | 30,550 | ||
| 2025-06-12 | Raman Prakash Director | Grant or award · Stock Option (Right to Buy) | +30,550 | 30,550 | ||
| 2025-06-12 | Campbell Shannon Director | Grant or award · Stock Option (Right to Buy) | +30,550 | 30,550 | ||
| 2025-06-12 | Dhingra Kapil Director | Grant or award · Stock Option (Right to Buy) | +30,550 | 30,550 | ||
| 2025-06-12 | Kulkarni Samarth Director | Grant or award · Stock Option (Right to Buy) | +30,550 | 30,550 | ||
| 2025-06-12 | Behbahani Ali Director | Grant or award · Stock Option (Right to Buy) | +30,550 | 30,550 | ||
| 2025-03-21 | Raman Prakash Director | Grant or award | +6,848 | $1.88 | $13K | 16,993 |
| 2025-03-21 | Behbahani Ali Director | Grant or award | +7,646 | $1.88 | $14K | 70,980 |
| 2025-03-19 | BIOTECH GROWTH N V 10% owner | Sale | −1,000,000 | $2.07 | $2.1M | 7,517,839 |
| 2025-03-19 | BIOTECH GROWTH N V 10% owner | Sale | −300,000 | $1.94 | $583K | 7,217,839 |
| 2025-03-19 | BIOTECH GROWTH N V 10% owner | Sale | −1,000,000 | $2.31 | $2.3M | 6,217,839 |
| 2025-03-19 | BIOTECH GROWTH N V 10% owner | Sale | −2,000,000 | $2.00 | $4.0M | 4,217,839 |
| 2025-03-19 | BIOTECH GROWTH N V 10% owner | Sale | −400,000 | $2.09 | $837K | 3,817,839 |
| 2025-03-19 | BIOTECH GROWTH N V 10% owner | Sale | −584,292 | $1.95 | $1.1M | 3,233,547 |
| 2025-03-19 | BIOTECH GROWTH N V 10% owner | Sale | −500,000 | $2.12 | $1.1M | 2,733,547 |
| 2025-01-30 | Velleca Mark A. PRESIDENT & CEO | Grant or award | +75,000 | 121,522 | ||
| 2025-01-30 | Velleca Mark A. PRESIDENT & CEO | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 |
Page 2 of 6 · 114 trades